Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis

• Published in: American journal of respiratory and critical care medicine Vol. 200; no. 11; pp. 1381 - 1391
• Main Authors: McElvaney, Oliver J., Zaslona, Zbigniew, Becker-Flegler, Katrin, Palsson-McDermott, Eva M., Boland, Fiona, Gunaratnam, Cedric, Gulbins, Erich, O’Neill, Luke A., Reeves, Emer P., McElvaney, Noel G.
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.12.2019
• Subjects: Animals; Anti-Inflammatory Agents - therapeutic use; Biomarkers - analysis; Bronchoalveolar Lavage Fluid - chemistry; Cystic fibrosis; Cystic Fibrosis - drug therapy; Furans - therapeutic use; Gram-negative bacteria; Humans; Inflammasomes - drug effects; Inflammation; Interleukin-1beta - analysis; Lung diseases; Mice; Neutrophils - drug effects; NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors; Pseudomonas Infections - etiology; Pseudomonas Infections - therapy; Sulfonamides - therapeutic use; MCC950; IL-1β; NLRP3 inflammasome; neutrophils; pyruvate kinase M2

Cystic fibrosis (CF) pulmonary disease is characterized by chronic infection with and sustained neutrophil-dominant inflammation. The lack of effective antiinflammatory therapies for people with CF (PWCF) represents a significant challenge. To identify altered immunometabolism in the CF neutrophil a...